DREAM-HF trial results highlight Mesoblast’s potential to differentiate in HF space: GlobalData
Revascor shows potential in reducing cardiovascular mortality and improving outcomes in high-risk heart failure patients, marking…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
cardiovascular
FINEARTS-HF trial results in clinically meaningful reduction in the composite endpoint of CV death
The study could be of high clinical value to cardiologists who are seeking an optimal treatment of choice for HF patients, which…
Lupin completes acquisition of two brands from Sanofi in Europe and Canada
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Lupin announced that its European…
Sanofi India, Emcure Pharma announce exclusive distribution partnership
Emcure to distribute and promote Sanofi’s cardiovascular brands in India